Cagrilintide vs Retatrutide: What the Research Shows
Cagrilintide and Retatrutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Cagrilintide if…
- you are weighing an investigational option (no FDA-approved product): in its phase 2 trial, mean weight reductions were greater with all cagrilintide doses than with placebo[9]
Consider Retatrutide if…
- you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
- you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[16]
What they have in common
Spec comparison
Showing 7 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Cagrilintide | Retatrutide |
|---|---|---|
| Class | Amylin analog | GLP-1 / GIP / glucagon triple agonist |
| Also called | cagri, cag | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Investigational (CagriSema component) | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Cagrilintide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Half-life | 159-195 h (with semaglutide 2.4 mg co-administered)subcutaneous · Lancet 2021, PMID 33894838 | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Clinical pharmacokinetics 2026, PMID 42228334 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 5 human (5 randomized or controlled) of 8 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2.5 mg, 5 mg, 10 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| Named in FDA warning letters, 2026 | Yes (31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Cagrilintide and Retatrutide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 22 results, 2 Oct 2026).
An amylin analogue versus a triple agonist: what the trials measured
Cagrilintide is an analogue of natural amylin, a pancreatic hormone that induces satiety.[9]
Retatrutide is a triple-receptor agonist acting at the GIP, GLP-1 and glucagon receptors.[1]
Cagrilintide's phase 2 trial was a dose-finding design that compared several weekly doses with a daily liraglutide arm and with placebo.[9]
Its treatment period was 26 weeks, including a dose-escalation period of up to 6 weeks.[9]
At the top cagrilintide dose, weight loss was greater than with the liraglutide comparator, and the reported difference was statistically significant.[9]
Retatrutide's TRIUMPH-1 randomised 2339 adults with obesity.[1]
It ran for 80 weeks at retatrutide doses of 4 mg, 9 mg or 12 mg against placebo.[1]
Knee osteoarthritis pain and sleep apnea were assessed in subgroups of that trial.[1]
A meta-analysis covering 5425 participants found cagrilintide monotherapy lowered body weight by 6.08% and lowered blood pressure, with no meaningful HbA1c improvement.[14]
Safety, kinetics and status
In the phase 1b trial cagrilintide had a half-life of 159-195 h across doses of 0.16-4.5 mg.[6]
A thorough QT study in 105 healthy participants found no clinically relevant QTc prolongation after the last 4.5 mg cagrilintide dose.[8]
In the cagrilintide phase 1b trial, every dose was given in combination with once-weekly semaglutide 2.4 mg.[6]
Retatrutide has no FDA record: the Drugs@FDA search returned no matches.[17]
Cagrilintide has none either: its Drugs@FDA search also returned no matches.[18]
Common questions
Cagrilintide vs retatrutide: which causes more weight loss?
They have not been compared head to head. Retatrutide's phase 3 and cagrilintide's phase 2 trials differ in length and design, so the headline percentages are not comparable.[1]
Is cagrilintide the same as CagriSema?
No. CagriSema is the combination of cagrilintide with semaglutide, and the meta-analysis reports cagrilintide and CagriSema results separately.[14]
Are cagrilintide and retatrutide approved?
Neither appears in the FDA approvals database: the searches for both returned no matches.[18]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
- 7Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
- 8Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
- 9Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
- 10LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 11Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 12Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 13PubMed search: (cagrilintide[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
- 15Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
- 16Official web pageOfficial web page · web page
- 17Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "cagrilintide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.